Xenikos
Developing a novel therapy that aims to reset the immune system of patients suffering from serious immune diseases or rejection after transplantation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | €2.5m | Grant | |
| Total Funding | 000k | ||
Related Content
Developer of anti-T-cell antibodies designed to provide immunotherapy medicines to help restore patients' health. The company uses a therapeutic tool for resetting the body's immune system which once injected into the body, specifically identifies and eliminates adult T cells, with a strong preference for the activated ones, enabling the medical community to optimize treatment outcomes associated with serious immune diseases.
Keywords: Pharmaceuticals and Biotechnology, Drug Development, Drug Development Firm, Drug Development Unit, Immune System, Immunotherapy Company, Immunotherapy Drugs, Immunotherapy Trials.